Literature DB >> 10204568

Inflammation of the brain in Alzheimer's disease: implications for therapy.

P L McGeer1, E G McGeer.   

Abstract

We briefly describe the similarities and differences between a systemic and a local immune reaction and review the evidence that the latter occurs in Alzheimer's disease (AD) brains. The evidence comes mainly from studies on the complement system, microglia, and cytokines, all of which are important actors in the inflammatory process. The evidence is now overwhelming that the complement proteins and many of the mediators of inflammation are produced locally by brain cells. We will mention briefly the many epidemiological studies indicating that the use of anti-inflammatory drugs reduces the incidence and slows the progress of AD. Mention will also be made of some recent work on animal models of possible relevance to AD and inflammation.

Entities:  

Mesh:

Year:  1999        PMID: 10204568     DOI: 10.1002/jlb.65.4.409

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  39 in total

1.  Continuous vaccinations of 4Aβ1-15 induces specific fluctuation of inflammatory factors accompany with pathologic alterations alleviation in APP/PS1 mice.

Authors:  Yuwei Zhang; Qingqing Li; Juntao Zou; Zejie Zuo; Zhibin Yao
Journal:  Hum Vaccin Immunother       Date:  2015-08-21       Impact factor: 3.452

Review 2.  Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.

Authors:  S R Barnum
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

3.  Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

Authors:  C K Combs; D E Johnson; J C Karlo; S B Cannady; G E Landreth
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 4.  T-cells in Alzheimer's disease.

Authors:  Terrence Town; Jun Tan; Richard A Flavell; Mike Mullan
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

5.  Ageing, science and the cosmetics industry. The micro-inflammatory model serves as a basis for developing effective anti-ageing products for the skin.

Authors:  Paolo U Giacomoni
Journal:  EMBO Rep       Date:  2005-07       Impact factor: 8.807

Review 6.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

7.  Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid.

Authors:  J J Yan; J Y Cho; H S Kim; K L Kim; J S Jung; S O Huh; H W Suh; Y H Kim; D K Song
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 8.  Molecular inflammation: underpinnings of aging and age-related diseases.

Authors:  Hae Young Chung; Matteo Cesari; Stephen Anton; Emanuele Marzetti; Silvia Giovannini; Arnold Young Seo; Christy Carter; Byung Pal Yu; Christiaan Leeuwenburgh
Journal:  Ageing Res Rev       Date:  2008-07-18       Impact factor: 10.895

9.  Salvianolic acid A, a polyphenolic derivative from Salvia miltiorrhiza bunge, as a multifunctional agent for the treatment of Alzheimer's disease.

Authors:  Ying Ying Cao; Ling Wang; Hu Ge; Xi Lin Lu; Zhong Pei; Qiong Gu; Jun Xu
Journal:  Mol Divers       Date:  2013-05-24       Impact factor: 2.943

10.  Dexamethasone, cerebrospinal fluid matrix metalloproteinase concentrations and clinical outcomes in tuberculous meningitis.

Authors:  Justin A Green; Chau T H Tran; Jeremy J Farrar; Mai T H Nguyen; Phu H Nguyen; Sinh X Dinh; Nghia D T Ho; Chuong V Ly; Hien T Tran; Jon S Friedland; Guy E Thwaites
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.